Arcellx, Inc., a clinical-stage biotechnology company developing immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, ACLX-001, ACLX-002, ACLX-003; and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in 2016/01. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, MD.